Effects of HMG CoA Reductase Inhibitors on Cholesterol Synthesis Alfred W. Alberts Section 1: Mechanism of Action 26 October 2012 Pages: 9 - 17
Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the Dog R. J. StubbsM. S. SchwartzW. F. Bayne Section 1: Mechanism of Action 26 October 2012 Pages: 18 - 28
Inhibition of Dietary Cholesterol Absorption During Lovastatin (Mevinolin) Treatment T. A. MiettinenM. J. TikkanenJ.-P. Ojala Section 1: Mechanism of Action 26 October 2012 Pages: 29 - 35
Enhanced Hepatic Uptake of Low Density Lipoprotein by Lovastatin (Mevinolin) in Man Markku J. SavolainenKari KervinenAntero Kesäniemi Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 37 - 39
Switch from Gemfibrozil to Lovastatin (Mevinolin) Therapy in Patients with Primary Hypercholesterolaemia Jukka-Pekka OjalaE. HelveJ. Viikari Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 40 - 47
Effect of Simvastatin Therapy on Apolipoproteins W. F. RiesenU. KellerF. W. Rentier Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 48 - 52
Efficacy and Tolerability of Simvastatin (Epistatin) in the Elderly J. Findlay WalkerRene A. PingeonDebora A. Shapiro Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 53 - 56
Discussion: Section 2 Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 57 - 57
Long Term Clinical Tolerance of Lovastatin (Mevinolin) and Simvastatin (Epistatin) David W. Bilheimer Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 58 - 67
Indications for the Use of HMG CoA Reductase Inhibitors Kurt Widhalm Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 68 - 73
Mechanistic and Clinical Rationale for the Use of HMG CoA Reductase Inhibitors in Prevention of Atherosclerosis Gert M. Kostner Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 74 - 75